Ophthotech Corp  

(Public, NASDAQ:OPHT)   Watch this stock  
Find more results for OPHT
53.01
-0.21 (-0.39%)
Real-time:   2:18PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 52.26 - 53.58
52 week 35.72 - 80.00
Open 53.48
Vol / Avg. 135,379.00/490,053.00
Mkt cap 1.92B
P/E     -
Div/yield     -
EPS -4.03
Shares 35.59M
Beta     -
Inst. own 100%
Nov 3, 2016
Q3 2016 Ophthotech Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 3, 2016
Q2 2016 Ophthotech Corp Earnings Release
Aug 3, 2016
Q2 2016 Ophthotech Corp Earnings Call - Webcast
Jun 7, 2016
Ophthotech Corp at Goldman Sachs Global Healthcare Conference
Jun 3, 2016
Ophthotech Corp Annual Shareholders Meeting (Estimated)
Jun 2, 2016
Ophthotech Corp Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -106.20% -205.26%
Operating margin -108.35% -239.84%
EBITD margin - -238.48%
Return on average assets -30.61% -23.27%
Return on average equity -503.31% -112.18%
Employees 116 -
CDP Score - -

Address

1 Penn Plz Fl 19
NEW YORK, NY 10119-0002
United States - Map
+1-212-8458200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.

Officers and directors

David R. Guyer Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Samirbhai C. Patel M.D. Vice Chairman of the Board, President
Age: 55
Bio & Compensation  - Reuters
Glenn P. Sblendorio Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer
Age: 60
Bio & Compensation  - Reuters
Barbara A. Wood Esq. Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Henric Bjorn Bjarke Senior Vice President and Chief Commercial Officer
Bio & Compensation  - Reuters
Douglas K. Kollmorgen Senior Vice President - Quality Assurance
Bio & Compensation  - Reuters
Harvey N. Masonson M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Loni da Silva Senior Vice President - Global Regulatory Affairs
Bio & Compensation  - Reuters
Todd N. Smith Senior Vice President, Chief Commercial Officer
Age: 45
Bio & Compensation  - Reuters
David Shima Chief Scientific Officer
Bio & Compensation  - Reuters